Skip to content

Study · Not a test of the peptide alone · 2006

3 results

Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction.

Chen M, Aprahamian CJ, Celik A, Georgeson KE, Garvey WT, Harmon CM, Yang Y

Biochemistry1 Jan 2006Cited by 36 (Europe PMC)

PMID16430209 (opens in a new tab)DOI10.1021/bi0521792 (opens in a new tab)PepBankPUB-16430209
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In cells expressing mutant MC3R, alanine substitutions of E131, D154, D158 and H298 dramatically reduced NDP-MSH binding affinity and receptor signaling.

    In plain wordsIn cells, changing four amino acids of the MC3R receptor sharply cut NDP-MSH binding and signaling.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH binding and signaling after charged residue substitutions
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    (i) substitutions of charged amino acid residues E131 in transmembrane domain 2 (TM2), D154 and D158 in TM3, and H298 in TM6 with alanine dramatically reduced NDP-MSH binding affinity and receptor signaling

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In cells expressing mutant MC3R, alanine substitutions of F295 and F296 in TM6 significantly decreased NDP-MSH binding and receptor activity.

    In plain wordsIn cells, changing two aromatic amino acids of the MC3R receptor lowered NDP-MSH binding and receptor activity.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH binding and activity after aromatic residue substitutions
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    (ii) substitutions of aromatic amino acids F295 and F296 in TM6 with alanine also significantly decreased NDP-MSH binding and receptor activity

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In cells expressing mutant MC3R, alanine substitutions of D121 and D332 caused complete loss of ligand binding, ligand-induced receptor activation and cell surface expression.

    In plain wordsIn cells, changing two amino acids of the MC3R receptor removed ligand binding and receptor activation completely.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseLigand binding and activation after D121 and D332 substitutions
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    (iii) substitutions of D121in TM2 and D332 in TM7 with alanine resulted in the complete loss of ligand binding, ligand induced receptor activation, and cell surface protein expression
    1 context sentence
    Summary · context
    Our results suggest that TM3 and TM6 are important for NDP-MSH binding, while D121 in TM2 and D332 in TM7 are crucial for receptor activity and signaling.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.